Develops gene therapies for genetic diseases.
Jun 2026Revenue $174M/yrExpenses $339M/yr
No trendCash runway ≈ 5 months from Jun 2026
Figures by year
When will REGENXBIO be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $174M and expenses $339M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $170M | $332M | −$161M |
| Dec 2024 | $83.3M | $317M | −$233M |
| Dec 2023 | $90.2M | $358M | −$268M |
| Dec 2022 | $113M | $376M | −$263M |
| Dec 2021 | $470M | $310M | $160M |
| Dec 2020 | $155M | $274M | −$119M |
| Dec 2019 | $35.2M | $184M | −$149M |
| Dec 2018 | $219M | $130M | $88.1M |
| Dec 2017 | $10.4M | $86.3M | −$75.9M |
| Dec 2016 | $4.59M | $69.9M | −$65.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.